Related Experiment Videos
E1A blocks hyperphosphorylation of p130 and p107 without affecting the phosphorylation status of the retinoblastoma
M Parreño1, J Garriga, A Limón
1Fels Institute for Cancer Research and Molecular Biology and Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
Abstract:
The phosphorylation status of the pRB family of growth suppressor proteins is regulated in a cell cycle entry-, progression-, and exit-dependent manner in normal cells. We have shown previously that p130, a member of this family, exhibits patterns of phosphorylated forms associated with various cell growth and differentiation stages. However, human 293 cells, which are transformed cells that express the adenoviral oncoproteins E1A and E1B, exhibit an abnormal pattern of p130 phosphorylated forms. Here we report that, unlike pRB, the phosphorylation status of both p130 and p107 is not modulated during the cell cycle in 293 cells as it is in other cells. Conditional overexpression of individual G(1)/S cyclins in 293 cells does not alter the phosphorylation status of p130, suggesting that the expression of E1A and/or E1B blocks hyperphosphorylation of p130. In agreement with these observations, transient cotransfection of vectors expressing E1A 12S, but not E1B, in combination with pocket proteins into U-2 OS cells blocks hyperphosphorylation of both p130 and p107. However, the phosphorylation status of pRB is not altered by cotransfection of E1A 12S vectors. Moreover, MC3T3-E1 preosteoblasts stably expressing E1A 12S also exhibit a block in hyperphosphorylation of endogenous p130 and p107. Direct binding of E1A to p130 and p107 is not required for the phosphorylation block since E1A 12S mutants defective in binding to the pRB family also block hyperphosphorylation of p130 and p107. Our data reported here identify a novel function of E1A, which affects p130 and p107 but does not affect pRB. Since E1A does not bind the hyperphosphorylated forms of p130, this function of E1A might prevent the existence of "free" hyperphosphorylated p130, which could act as a CDK inhibitor.
Insights
Adenoviral E1A protein prevents cell cycle-dependent hyperphosphorylation of p130 and p107 proteins in transformed cells. This novel E1A function impacts p130 and p107, but not pRB, independent of direct binding.
Area of Science:
- Molecular Biology
- Cell Biology
- Virology
Background:
- The retinoblastoma protein (pRB) family regulates cell cycle progression.
- pRB family members p130 and p107 show cell cycle-dependent phosphorylation patterns in normal cells.
- Human 293 cells, expressing adenoviral oncoproteins E1A and E1B, display aberrant p130 phosphorylation.
Purpose of the Study:
- To investigate the effect of adenoviral E1A and E1B oncoproteins on the cell cycle-dependent phosphorylation of pRB family members p130 and p107.
- To determine if E1A binding to p130 and p107 is necessary for modulating their phosphorylation status.
Main Methods:
- Analysis of p130 and p107 phosphorylation in human 293 cells.
- Conditional overexpression of G(1)/S cyclins in 293 cells.
- Transient cotransfection of E1A and E1B expression vectors into U-2 OS cells.
- Stable expression of E1A 12S in MC3T3-E1 preosteoblasts.
- Analysis of E1A mutants defective in pRB family binding.
Main Results:
- Unlike normal cells, p130 and p107 phosphorylation is not modulated during the cell cycle in 293 cells.
- E1A and/or E1B expression blocks p130 hyperphosphorylation in 293 cells.
- E1A 12S, but not E1B, blocks p130 and p107 hyperphosphorylation in U-2 OS cells and MC3T3-E1 cells.
- E1A 12S blocks p130 and p107 hyperphosphorylation independently of direct binding to these proteins.
- E1A 12S does not affect pRB phosphorylation status.
Conclusions:
- Adenoviral E1A protein possesses a novel function to block p130 and p107 hyperphosphorylation in a cell cycle-independent manner.
- This E1A function is distinct from its effect on pRB and does not require direct binding to p130 or p107.
- E1A may prevent the formation of free hyperphosphorylated p130, potentially inhibiting CDK activity.